LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Changes to the Post-Acute Care System of Care: The Effect of Consolidation of Ownership by For-Profit Facilities in the United States.

    Meythaler, Jay M

    Archives of physical medicine and rehabilitation

    2023  Volume 105, Issue 3, Page(s) 611–614

    MeSH term(s) United States ; Humans ; Ownership ; Subacute Care
    Language English
    Publishing date 2023-10-31
    Publishing country United States
    Document type Editorial
    ZDB-ID 80057-0
    ISSN 1532-821X ; 0003-9993
    ISSN (online) 1532-821X
    ISSN 0003-9993
    DOI 10.1016/j.apmr.2023.03.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Proposed Changes to the Inpatient Services for the Disabled in the United States Post-COVID-19.

    Meythaler, Jay M

    Archives of physical medicine and rehabilitation

    2020  Volume 101, Issue 8, Page(s) 1473–1474

    MeSH term(s) Betacoronavirus ; COVID-19 ; Centers for Medicare and Medicaid Services, U.S. ; Coronavirus Infections/epidemiology ; Disabled Persons/rehabilitation ; Humans ; Inpatients ; Pandemics ; Pneumonia, Viral/epidemiology ; Prospective Payment System ; Rehabilitation Centers/economics ; Rehabilitation Centers/organization & administration ; SARS-CoV-2 ; Skilled Nursing Facilities/economics ; Skilled Nursing Facilities/organization & administration ; United States/epidemiology
    Keywords covid19
    Language English
    Publishing date 2020-05-11
    Publishing country United States
    Document type Editorial
    ZDB-ID 80057-0
    ISSN 1532-821X ; 0003-9993
    ISSN (online) 1532-821X
    ISSN 0003-9993
    DOI 10.1016/j.apmr.2020.05.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Commentary: Associations Between Adherence to the Intervention Applied in the LAST Study (Life After Stroke) and Functional Outcome After Stroke.

    Meythaler, Jay M

    Archives of physical medicine and rehabilitation

    2019  Volume 100, Issue 12, Page(s) 2409–2410

    MeSH term(s) Exercise ; Exercise Therapy ; Humans ; Recovery of Function ; Stroke
    Language English
    Publishing date 2019-11-25
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80057-0
    ISSN 1532-821X ; 0003-9993
    ISSN (online) 1532-821X
    ISSN 0003-9993
    DOI 10.1016/j.apmr.2019.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Proposed Changes to the Inpatient Services for the Disabled in the United States Post–COVID-19

    Meythaler, Jay M.

    Archives of Physical Medicine and Rehabilitation

    2020  Volume 101, Issue 8, Page(s) 1473–1474

    Keywords Physical Therapy, Sports Therapy and Rehabilitation ; Rehabilitation ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 80057-0
    ISSN 1532-821X ; 0003-9993
    ISSN (online) 1532-821X
    ISSN 0003-9993
    DOI 10.1016/j.apmr.2020.05.001
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Book: Spastic hypertonia

    Meythaler, Jay M.

    (Physical medicine and rehabilitation clinics of North America ; 12,4)

    2001  

    Author's details guest ed. Jay M. Meythaler
    Series title Physical medicine and rehabilitation clinics of North America ; 12,4
    Collection
    Language English
    Size IX S., S. 725 - 977 : Ill.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT013202150
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Article ; Online: Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome.

    Meythaler, Jay M / Brunner, Robert C / Peduzzi, Jean

    Archives of rehabilitation research and clinical translation

    2021  Volume 3, Issue 2, Page(s) 100123

    Abstract: Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine (4-AP) in persons with Guillain-Barré Syndrome (GBS) >6 months from initial diagnosis.: Design: A randomized, double-blind, placebo-controlled, crossover study.: ... ...

    Abstract Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine (4-AP) in persons with Guillain-Barré Syndrome (GBS) >6 months from initial diagnosis.
    Design: A randomized, double-blind, placebo-controlled, crossover study.
    Setting: Tertiary care clinical outpatient program.
    Participants: Nineteen participants enrolled (14 male, 5 female; N=19), neurologic impairment secondary to GBS and functional loss on the FIM motor score (stable for ≥12mo) and >3.0 but <5.0 on the American Spinal Injury motor scale. Twelve participants (mean age, 59y; range, 23-77y) completed the study.
    Interventions: A 4-AP dose-escalation study with 8 weeks in each period with a 3-week washout period, followed by 3 months open-label follow-up.
    Main outcome measures: FIM motor score was the primary outcome measure; also evaluated were the American Spinal Injury motor strength score (all limbs), handheld dynamometer, 6-minute walk test, Medical Outcomes Study 12-Item Short Form, Center for Epidemiological Studies Depression scale, Positive and Negative Affect Schedule, pain, GBS disability scale, Jepsen-Taylor Hand Function Test, Minnesota Manual Dexterity Test and Minnesota Rate of Manipulation Test, Get Up and Go Test, McGill Pain Inventory, Craig Handicap Assessment and Reporting Technique, and participant self-evaluation.
    Results: Seven participants discontinued the study prematurely: 3 because of adverse events, 3 because of travel difficulties or relocation, and 1 because of pretreatment laboratory abnormalities. After removing 3 participants with maximum FIM scores, 4-AP arm trended superior to placebo (
    Conclusions: This study demonstrates the safety of 4-AP in the patient population with GBS as the predominate goal of the study. A trend toward improved function after treatment was noted with most patients electing to stay on the medication after the trial.
    Language English
    Publishing date 2021-04-08
    Publishing country United States
    Document type Journal Article
    ISSN 2590-1095
    ISSN (online) 2590-1095
    DOI 10.1016/j.arrct.2021.100123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Intranasally applied human olfactory mucosa neural progenitor cells migrate to damaged brain regions.

    Kronner, John M / Folbe, Adam / Meythaler, Jay / Nelson, John O / Borisov, Andrei / Peduzzi, Jean D

    Future science OA

    2022  Volume 8, Issue 6, Page(s) FSO806

    Abstract: Aim: To determine if intranasally administered olfactory mucosa progenitor cells (OMPCs) migrate to damaged areas of brain.: Materials & methods: Rowett Nude (RNU) adult rats were injured using the Marmarou model then 2 weeks later received ... ...

    Abstract Aim: To determine if intranasally administered olfactory mucosa progenitor cells (OMPCs) migrate to damaged areas of brain.
    Materials & methods: Rowett Nude (RNU) adult rats were injured using the Marmarou model then 2 weeks later received intranasally-delivered human OMPC. After 3 weeks, rats were sacrificed and brain sectioned. The mean distances from the human OMPCs to markers for degenerative neuronal cell bodies (p-c-Jun
    Results: The human OMPCs were seen in specific areas of the brain near degenerating cell bodies and damaged axons.
    Conclusion: Intranasally delivered human OMPC selectively migrate to brain injury sites suggesting a possible noninvasive stem cell delivery for brain injury.
    Language English
    Publishing date 2022-07-12
    Publishing country England
    Document type Journal Article
    ISSN 2056-5623
    ISSN 2056-5623
    DOI 10.2144/fsoa-2022-0012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Baclofen Solution for Low-Volume Therapeutic Delivery.

    Meythaler, Jay M / Peduzzi, Jean D

    Neuromodulation : journal of the International Neuromodulation Society

    2016  Volume 20, Issue 4, Page(s) 392–396

    Abstract: Objectives: Baclofen is a zwitterion molecule where increased ions in the excipient increase the solubility. We developed baclofen in a stable solution similar to cerebrospinal fluid (CSF) without bicarbonate and proteins to improve the solubility of ... ...

    Abstract Objectives: Baclofen is a zwitterion molecule where increased ions in the excipient increase the solubility. We developed baclofen in a stable solution similar to cerebrospinal fluid (CSF) without bicarbonate and proteins to improve the solubility of the baclofen and to reduce the potential toxicity to the central nervous system (CNS) and subarachnoid space. The objective is to develop a solution of baclofen wherein baclofen is solubilized in a multivalent physiological ion solution such as artificial cerebrospinal fluid (aCSF) at a concentration from 2 mg/cc to 10 mg/cc.
    Methods: First, to determine the solubility of Baclofen in aCSF, solubility was determined at six different pH levels at 37°C, by the addition of aCSF to a known amount of Baclofen. The final concentrations were confirmed by high performance liquid chromatography (HPLC) analysis. Second, the stability of Baclofen at 4 mg/cc investigated in a test manufacturing batch utilizing standard methods of production of 1500 20 cc vials inverted for 18 months at 25°C at 60% humidity. The stability and purity of the baclofen was verified at 18 months by HPLC analysis.
    Results: Baclofen was initially soluble between pH of 6-8 above 7 mg/cc but fell back to 6.3-5.8 mg/cc level with time. Baclofen produced in vials with inversion were noted to be stable at 4 mg/cc at 18 months with less than 2% breakdown of the baclofen in solution.
    Conclusion: Baclofen is much more soluble in artificial CSF than normal saline. The artificial CSF may also be less toxic to the subarachnoid space than saline.
    MeSH term(s) Baclofen/administration & dosage ; Baclofen/chemistry ; Drug Delivery Systems/methods ; Drug Delivery Systems/standards ; Drug Stability ; Humans ; Infusion Pumps, Implantable ; Muscle Relaxants, Central/administration & dosage ; Muscle Relaxants, Central/chemistry ; Pharmaceutical Solutions/administration & dosage ; Pharmaceutical Solutions/chemistry
    Chemical Substances Muscle Relaxants, Central ; Pharmaceutical Solutions ; Baclofen (H789N3FKE8)
    Language English
    Publishing date 2016-10-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1500372-3
    ISSN 1525-1403 ; 1094-7159
    ISSN (online) 1525-1403
    ISSN 1094-7159
    DOI 10.1111/ner.12528
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome

    Jay M. Meythaler, JD, MD / Robert C. Brunner, MD / Jean Peduzzi, PhD

    Archives of Rehabilitation Research and Clinical Translation, Vol 3, Iss 2, Pp 100123- (2021)

    2021  

    Abstract: Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine (4-AP) in persons with Guillain-Barré Syndrome (GBS) >6 months from initial diagnosis. Design: A randomized, double-blind, placebo-controlled, crossover study. Setting: ... ...

    Abstract Objective: To determine the safety and efficacy of orally delivered 4-aminopyridine (4-AP) in persons with Guillain-Barré Syndrome (GBS) >6 months from initial diagnosis. Design: A randomized, double-blind, placebo-controlled, crossover study. Setting: Tertiary care clinical outpatient program. Participants: Nineteen participants enrolled (14 male, 5 female; N=19), neurologic impairment secondary to GBS and functional loss on the FIM motor score (stable for ≥12mo) and >3.0 but <5.0 on the American Spinal Injury motor scale. Twelve participants (mean age, 59y; range, 23-77y) completed the study. Interventions: A 4-AP dose-escalation study with 8 weeks in each period with a 3-week washout period, followed by 3 months open-label follow-up. Main Outcome Measures: FIM motor score was the primary outcome measure; also evaluated were the American Spinal Injury motor strength score (all limbs), handheld dynamometer, 6-minute walk test, Medical Outcomes Study 12-Item Short Form, Center for Epidemiological Studies Depression scale, Positive and Negative Affect Schedule, pain, GBS disability scale, Jepsen-Taylor Hand Function Test, Minnesota Manual Dexterity Test and Minnesota Rate of Manipulation Test, Get Up and Go Test, McGill Pain Inventory, Craig Handicap Assessment and Reporting Technique, and participant self-evaluation. Results: Seven participants discontinued the study prematurely: 3 because of adverse events, 3 because of travel difficulties or relocation, and 1 because of pretreatment laboratory abnormalities. After removing 3 participants with maximum FIM scores, 4-AP arm trended superior to placebo (P=.065). Patients subjectively could always tell when they were on the active agent usually by tingling sensations or a sense of wellness. No statistically significant differences were found for other outcome measures although there were strong trends. Conclusions: This study demonstrates the safety of 4-AP in the patient population with GBS as the predominate goal of the study. A trend toward improved ...
    Keywords Demyelinating diseases ; 4-Aminopyridine ; Guillain-Barre syndrome ; Rehabilitation ; Medicine (General) ; R5-920
    Subject code 796
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top